文献速递前列腺癌男科与性医学

质子泵抑制剂与前列腺癌特异性死亡的不良关联:一项基于人群的队列研究

The deleterious association between proton pump inhibitors and prostate cancer-specific mortality - a population-based cohort study.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-07-08

该研究基于加拿大21,512名≥66岁、有单次阴性前列腺活检史的男性,评估质子泵抑制剂(PPI)与前列腺癌特异性死亡(PCSM)、雄激素剥夺治疗(ADT)使用及前列腺癌诊断的关联。中位随访8.06年,潘托拉唑每累积使用6个月与ADT使用率增加3.0%(95%CI 0.3-6.0%)相关,其他PPI任何使用与PCSM风险增加39.0%(95%CI 18.0-64.0%)相关,未发现与前列腺癌诊断的关联。

要点

  • 其他PPI任何使用与前列腺癌特异性死亡风险增加39.0%相关
  • 潘托拉唑每累积6个月与ADT使用率增加3.0%相关
  • 未发现PPI使用与前列腺癌诊断存在关联

核心结论

  • PPI使用可能与前列腺癌特异性死亡及ADT使用增加相关,需在前列腺癌患者中重新评估PPI使用。

研究设计与样本

  • 基于加拿大大型人群的队列研究,纳入21,512名≥66岁、有单次阴性前列腺活检史且既往未使用分析药物的男性(1994-2016年)。
  • 采用多变量Cox回归模型(含时间依赖协变量),调整年龄、城乡、合并症及入组年份,并纳入其他潜在化学预防药物。

主要发现

  • 平均随访8.06年(SD 5.44年),10,999例(51.1%)使用PPI,5,187例(24.1%)诊断为前列腺癌,2,043例(9.5%)接受ADT,805例(3.7%)死于前列腺癌。
  • 潘托拉唑每累积使用6个月与ADT使用率增加3.0%(95%CI 0.3-6.0%)相关。
  • 其他PPI任何使用与前列腺癌特异性死亡风险增加39.0%(95%CI 18.0-64.0%)相关。
  • 未发现PPI使用与前列腺癌诊断存在关联。

临床怎么用

  • 对于前列腺癌患者,尤其是需要使用PPI者,应重新评估PPI处方的必要性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Proton pump inhibitors (PPIs) are commonly prescribed medications that have been shown to have contradicting effects on cancer. We aimed to investigate the effect of pantoprazole and other PPIs on prostate cancer (PCa) specific mortality (PCSM), use of androgen deprivation therapy (ADT), and PCa diagnosis using a large Canadian population-based cohort. METHODS: We identified 21,512 men aged ≥ 66, with a history of a single negative prostate biopsy and no previous use of any of the analyzed medications between 1994 and 2016. Multivariable Cox regression models with time-dependent covariates were used to assess the associations of PPIs with PCa outcomes. All models included other medications with a putative chemopreventative effect on PCa-outcomes, and were adjusted for age, rurality, comorbidity, and study inclusion year. RESULTS: Over a mean follow-up of 8.06 years (SD 5.44 years), 10,999 patients (51.1%) used a PPI, 5187 patients (24.1%) had PCa, 2043 patients (9.5%) were treated with ADT, and 805 patients (3.7%) died from PCa. For every 6 months of cumulative use, pantoprazole was associated with a 3.0% (95% CI 0.3-6.0%) increased rate of ADT use, while any use of other PPIs was associated with a 39.0% (95% CI 18.0-64.0%) increased risk of PCSM. No association was found with PCa diagnosis. CONCLUSIONS: Upon validation of the potentially negative association of PPIs with PCa, PPI use may need to be reassessed in PCa patients.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Goldberg H, Mohsin FK, Saskin R, et al. The deleterious association between proton pump inhibitors and prostate cancer-specific mortality - a population-based cohort study. Prostate Cancer Prostatic Dis. 2020. PMID: 32641738. doi:10.1038/s41391-020-0248-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。